Teva Pharmaceutical Industries News

Express News | NYSE Order Imbalance 129390.0 Shares on Buy Side

Breakings03:50

Teva Pharmaceuticals Is Maintained at Buy by B of A Securities

Teva Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow JonesMay 30 23:55

Teva Pharmaceutical Indus Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/30/2024 27.12% B of A Securities $18 → $21 Maintains Buy 05/13/2024 21.07% Piper Sandler $19 → $20 Reit

BenzingaMay 30 23:44

Teva Wins FDA Nod for New Austedo Formulation

Seeking AlphaMay 30 19:33

Express News | Teva : BofA Global Research Raises Price Objective to $21 From $18

BreakingsMay 30 19:11

Reported Earlier, Teva's AUSTEDO XR Receives FDA Green Light, One Pill, Once-Daily Dosage Now Available For TD And HD Chorea

U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day)AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular monoamine transporter 2 (VMAT2)

BenzingaMay 30 15:16

Express News | NYSE Order Imbalance 117996.0 Shares on Sell Side

BreakingsMay 30 03:50

Teva Announces AUSTEDO XR (Deutetrabenazine) Extended-Release Tablets Now U.S. FDA Approved as a One Pill, Once-Daily Treatment Option for Clinically Therapeutic Doses (24–48 Mg/day)

U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day) AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular monoamine transporter 2 (VMA

Teva PharmaceuticMay 29 12:00

Press Release: Medincell: Update of the 2024 Financial Calendar

Medincell: Update of the 2024 Financial Calendar MONTPELLIER, France--(BUSINESS WIRE)--May 27, 2024-- Regulatory News: Medincell (Paris:MEDCL) announces an update to its 2024 financial agenda: Eve

Dow JonesMay 28 00:00

Global Topical Wound Agents Market Size To Exceed USD 3.7 Billion By 2033 | CAGR Of 6.89%

Yahoo FinanceMay 26 04:00

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

The Teva Pharmaceutical Industries Limited (NYSE:TEVA) share price has done very well over the last month, posting an excellent gain of 28%. The last month tops off a massive increase of 123% in th

Simply Wall StMay 25 22:42

Barclays Maintains Teva Pharmaceutical Industries(TEVA.US) With Buy Rating, Maintains Target Price $20

Barclays analyst Balaji Prasad maintains $Teva Pharmaceutical Industries(TEVA.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate o

Futu NewsMay 24 16:32

Teva Pharmaceutical Indus's Options Frenzy: What You Need to Know

Investors with a lot of money to spend have taken a bearish stance on Teva Pharmaceutical Indus (NYSE:TEVA).And retail traders should know.We noticed this today when the positions showed up on publicl

BenzingaMay 23 00:01

Teva, Alvotech Launch Biosimilar Against AbbVie's Humira

Seeking AlphaMay 21 18:51

Reported Earlier, Teva And Alvotech Announce U.S. Launch Of Simlandi (Adalimumab-ryvk), The First Interchangeable High-Concentration, Citrate-Free Biosimilar To Humira

Reported Earlier, Teva And Alvotech Announce U.S. Launch Of Simlandi (Adalimumab-ryvk), The First Interchangeable High-Concentration, Citrate-Free Biosimilar To Humira

BenzingaMay 21 14:57

Teva Pharmaceutical Industries Options Spot-On: On May 20th, 90,889 Contracts Were Traded, With 900.4K Open Interest

On May 20th ET, $Teva Pharmaceutical Industries(TEVA.US)$ had active options trading, with a total trading volume of 90,889 options for the day, of which put options accounted for 3.07% of the total t

Futu NewsMay 21 04:30

Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch

President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA). This shift could revolutionize the cannabis industry. B

BenzingaMay 18 22:19

Insider Sale: Chief Accounting Officer Amir Weiss Sells 28,135 Shares of Teva Pharmaceutical ...

Yahoo FinanceMay 17 23:00

Teva Pharmaceutical Industries Insider Sold Shares Worth $470,794, According to a Recent SEC Filing

Amir Weiss, Chief Accounting Officer, around May 15, 2024, sold 28,135 shares in Teva Pharmaceutical Industries (TEVA) for $470,794. Following the Form 4 filing with the SEC, Weiss has control over a

MT NewswiresMay 17 21:06

Teva Pharmaceutical Industries(TEVA.US) Officer Sells US$470.79K in Common Stock

$Teva Pharmaceutical Industries(TEVA.US)$ Officer Weiss Amir sold 28,135 shares of common stock on May 15, 16, 2024 at an average price of $16.7334 for a total value of $470.79K.Source: Announcement W

Futu NewsMay 17 20:21